Advertisement
Advertisement

Health

Diabetes study finds keeping blood sugar too steady may come at a price

People with diabetes reported better quality of life after days when their glucose stayed largely within a healthy range, even when levels fluctuated more than usual. The unexpected finding suggests that pursuing extremely tight glucose control may sometimes come with a hidden lifestyle burden.

Blood tests reveal why astronauts get constipated in space

Spaceflight may dramatically change the gut within weeks, causing bacteria to break down more protein as food moves more slowly through the intestines. The shift could help explain astronaut constipation and may have wider effects on health, making it an important concern for future missions to Mars.

Advertisement

Glucosamine, a popular joint supplement, linked to faster Alzheimer’s progression

A large health-record analysis found that glucosamine use was associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia. Lab experiments suggest the popular joint supplement may intensify an abnormal sugar-tagging process in the Alzheimer’s brain, although researchers say clinical trials are needed to determine whether it actually causes harm.

A major risk of breast cancer screening may have been overestimated for decades

A new analysis suggests mammograms may lead to far less breast cancer overdiagnosis than some earlier studies indicated. Researchers reexamined all eight major randomized screening trials and accounted for differences in follow-up time, screening frequency, and screening after trials ended. Their results were consistent with an overdiagnosis rate below 5%, rather than estimates approaching 30% to 50%.

Advertisement

CRISPR could help doctors attack blood cancer without destroying healthy cells

Researchers used CRISPR to remove CD33 from donor stem cells, potentially giving doctors a way to attack aggressive blood cancers without destroying the healthy cells patients need after a transplant. In a 30-patient trial, the edited cells successfully took hold and appeared to shield blood cells from a CD33-targeted cancer treatment.